FDA Issues Complete Response Letter for Lead SMA Drug Apitegromab, Delaying Commercialization

summarizeSummary

Scholar Rock received a Complete Response Letter (CRL) from the FDA for its lead SMA drug, apitegromab, delaying commercialization. The company reported a widened net loss and increased cash burn, while securing a new $350.0 million debt facility to fund operations into 2027.

check_boxKey Events

• FDA Issues Complete Response Letter for Apitegromab

  The FDA issued a CRL in September 2025 for apitegromab's BLA due to site-related observations at a third-party fill-finish facility, delaying the anticipated 2026 commercial launch. The company plans to resubmit the BLA after cGMP deficiencies are resolved.

• Widened Net Loss and Increased Cash Burn

  Scholar Rock reported a net loss of $377.9 million for 2025, significantly wider than $246.3 million in 2024. Cash used in operating activities increased to $300.0 million in 2025 from $200.9 million in 2024.

• Secured New $350 Million Debt Facility

  In February 2026, the company entered into a new $350.0 million debt facility with Blue Owl, using an initial $100.0 million draw to repay its previous $103.7 million outstanding debt with Oxford Finance LLC. An additional $100.0 million is available until March 31, 2026, and $150.0 million after FDA approval of apitegromab.

• Liquidity Runway into 2027

  Existing cash, cash equivalents, and marketable securities of $367.6 million as of December 31, 2025, combined with available debt, are expected to fund operations into 2027.

auto_awesomeAnalysis

Scholar Rock Holding Corp's annual report highlights a significant setback with the FDA issuing a Complete Response Letter (CRL) in September 2025 for its lead product candidate, apitegromab, for spinal muscular atrophy (SMA). This CRL, stemming from observations at a third-party fill-finish facility, delays the anticipated commercialization in 2026 and necessitates a resubmission of the Biologics License Application (BLA) after the facility resolves cGMP deficiencies. This regulatory delay is a material negative event, impacting the company's near-term revenue prospects and increasing uncertainty. Concurrently, the company reported a widened net loss of $377.9 million for 2025, up from $246.3 million in 2024, and increased cash used in operating activities to $300.0 million. To address liquidity, Scholar Rock secured a new $350.0 million debt facility with Blue Owl in February 2026, using $100.0 million to repay existing debt. While this provides capital runway, it also adds to the company's liabilities. The company continues to advance its pipeline, with positive Phase 3 data for apitegromab in SMA, a Phase 2 study for apitegromab in FSHD expected to initiate mid-2026, and encouraging Phase 1 data for SRK-181 in solid tumors. However, the immediate impact of the CRL on its most advanced program is paramount. The company also noted it no longer qualifies as a 'smaller reporting company,' which will lead to increased compliance costs.